-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Private Companies Are Shanghai Labway Clinical Laboratory Co., Ltd.'s (SZSE:301060) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.3b
Private Companies Are Shanghai Labway Clinical Laboratory Co., Ltd.'s (SZSE:301060) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.3b
A look at the shareholders of Shanghai Labway Clinical Laboratory Co., Ltd. (SZSE:301060) can tell us which group is most powerful. The group holding the most number of shares in the company, around 54% to be precise, is private companies. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
And following last week's 10% decline in share price, private companies suffered the most losses.
Let's delve deeper into each type of owner of Shanghai Labway Clinical Laboratory, beginning with the chart below.
View our latest analysis for Shanghai Labway Clinical Laboratory
SZSE:301060 Ownership Breakdown September 11th 2022What Does The Institutional Ownership Tell Us About Shanghai Labway Clinical Laboratory?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
Institutions have a very small stake in Shanghai Labway Clinical Laboratory. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.
SZSE:301060 Earnings and Revenue Growth September 11th 2022Hedge funds don't have many shares in Shanghai Labway Clinical Laboratory. The company's largest shareholder is Shanghai Lanwei Investment Co., Ltd., with ownership of 37%. Weixiong Zeng is the second largest shareholder owning 13% of common stock, and Heilan Group Co., Ltd. holds about 11% of the company stock. Weixiong Zeng, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Shanghai Labway Clinical Laboratory
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our information suggests that insiders maintain a significant holding in Shanghai Labway Clinical Laboratory Co., Ltd.. Insiders own CN¥1.8b worth of shares in the CN¥11b company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
General Public Ownership
The general public, who are usually individual investors, hold a 25% stake in Shanghai Labway Clinical Laboratory. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
It seems that Private Companies own 54%, of the Shanghai Labway Clinical Laboratory stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Shanghai Labway Clinical Laboratory better, we need to consider many other factors. Case in point: We've spotted 2 warning signs for Shanghai Labway Clinical Laboratory you should be aware of, and 1 of them shouldn't be ignored.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看看上海朗威临床实验室股份有限公司(深交所股票代码:301060)的股东,就知道哪个集团最有权势。持有该公司股份最多的集团,准确地说约为54%,是私营公司。也就是说,如果股价上涨,该集团将受益最大(如果股价下跌,该集团将损失最大)。
继上周股价下跌10%之后,私营企业遭受的损失最大。
让我们从下面的图表开始,更深入地了解上海朗威临床实验室的每种类型的所有者。
查看我们对上海朗威临床实验室的最新分析
深交所:301060所有权明细2022年9月11日机构所有制对上海朗威临床实验室有何启示?
许多机构以一个接近当地市场的指数来衡量它们的表现。因此,他们通常更关注那些被纳入主要指数的公司。
医疗机构在上海朗威临床实验室的持股比例非常低。这表明该公司受到了一些基金的关注,但目前并不是特别受专业投资者的欢迎。如果业务从现在开始变得更强劲,我们可能会看到更多机构热衷于购买的情况。当多家机构投资者想要购买股票时,我们经常会看到股价上涨。过去的收入轨迹(如下所示)可以预示未来的增长,但这并不能保证。
深交所:2022年9月11日收益和收入增长301060对冲基金在上海朗威临床实验室的股份并不多。该公司第一大股东为上海蓝威投资有限公司,持股37%。曾伟雄为第二大股东,持有13%的普通股,海澜集团股份有限公司持有公司约11%的股份。作为第二大股东的曾伟雄也恰好持有首席执行官的头衔。
为了让我们的研究更有趣,我们发现,前两名股东拥有公司的多数股权,这意味着他们足够强大,可以影响公司的决策。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。据我们所知,没有分析师对该公司的报道,所以它很可能在雷达下飞行。
上海朗威临床实验室的内部人所有权
不同国家对内部人的定义可能略有不同,但董事会成员总是算数的。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
我们的信息显示,内部人士持有上海朗威临床实验室有限公司的大量股份。内部人士在这家价值110亿元的公司中持有价值18亿元的股份。这是很有意义的。大多数人会高兴地看到董事会与他们一起投资。你可能希望访问这张显示内部人士最近交易的免费图表。
一般公有制
公众通常是个人投资者,他们持有上海朗威临床实验室25%的股份。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私营公司所有权
看起来,民营企业持有上海朗威临床实验室54%的股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但为了更好地了解上海朗威临床实验室,我们还需要考虑许多其他因素。一个恰当的例子:我们发现了上海朗威临床实验室的2个警示标志你应该意识到,其中有一个是不应该被忽视的。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费令人感兴趣的公司名单,有强劲的财务数据支持。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧